▲ 0.47%
prev close
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
Congressional Trades
1
All tracked trades
Members Trading
1
Unique members
Net Activity
-1
0 buys · 1 sells
Members Who Traded This Stock
1 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2025-03-25 | INVAInnoviva, Inc. - Common Stock | Sell | $250,001 - $500,000 | 344d ago | — |
2025-03-25
George Whitesides
INVA
Amount
$250,001 - $500,000
Filed
344d ago
Recent News
Powered by Polygon.io
Tetracyclines Market is Poised to Garner Valuation of USD 5.63 Billion by 2035 | Astute Analytica
Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out
Innoviva (INVA) Q2 Sales Jump 64%
Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States
Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs
Trade Timeline
Congressional activity, newest first
George Whitesides
2025-03-25 · Sale
$250,001 - $500,000